{"filing":{"accession_number":"0001437749-26-021350","cik":"0001645469","ticker":"MNPR","company_name":"Monopar Therapeutics","form":"8-K","filing_date":"2026-06-23","report_date":null,"primary_document":"mnpr20260622_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926021350/mnpr20260622_8k.htm"},"events":[{"id":13007,"run_id":11547,"accession_number":"0001437749-26-021350","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure reporting the results of Monopar's Annual Meeting held on June 22, 2026. The filing presents voting outcomes for four proposals: election of six directors (all elected), advisory approval of NEO compensation, approval of the 2026 Stock Incentive Plan, and ratification of BPM LLP as independent auditor. All proposals passed with substantial majorities, making this a standard shareholder vote results disclosure that is material to investors' understanding of governance and board composition.","company_name":"Monopar Therapeutics","ticker":"MNPR","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":10021,"accession_number":"0001437749-26-021350","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Monopar's Annual Meeting held on June 22, 2026. The filing presents voting outcomes for four proposals: election of six directors (all elected), advisory approval of NEO compensation, approval of the 2026 Stock Incentive Plan, and ratification of BPM LLP as independent auditor. All proposals passed with substantial majorities, making this a standard shareholder vote results disclosure that is material to investors' understanding of governance and board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T12:01:54.049728+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10021,"accession_number":"0001437749-26-021350","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Monopar's Annual Meeting held on June 22, 2026. The filing presents voting outcomes for four proposals: election of six directors (all elected), advisory approval of NEO compensation, approval of the 2026 Stock Incentive Plan, and ratification of BPM LLP as independent auditor. All proposals passed with substantial majorities, making this a standard shareholder vote results disclosure that is material to investors' understanding of governance and board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T12:01:54.049728+00:00","company_name":"Monopar Therapeutics","ticker":"MNPR","filing_date":"2026-06-23"}]}